HK1151191A1 - Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis - Google Patents

Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis

Info

Publication number
HK1151191A1
HK1151191A1 HK11105315.4A HK11105315A HK1151191A1 HK 1151191 A1 HK1151191 A1 HK 1151191A1 HK 11105315 A HK11105315 A HK 11105315A HK 1151191 A1 HK1151191 A1 HK 1151191A1
Authority
HK
Hong Kong
Prior art keywords
treatment
cystic fibrosis
tobramycin combination
fosfomycin
aerosolized
Prior art date
Application number
HK11105315.4A
Other languages
English (en)
Inventor
William Baker
David Macleod
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1151191A1 publication Critical patent/HK1151191A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK11105315.4A 2004-05-17 2011-05-27 Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis HK1151191A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57173904P 2004-05-17 2004-05-17
US65900505P 2005-03-03 2005-03-03

Publications (1)

Publication Number Publication Date
HK1151191A1 true HK1151191A1 (en) 2012-01-27

Family

ID=35394588

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11105315.4A HK1151191A1 (en) 2004-05-17 2011-05-27 Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis
HK11111954.8A HK1157637A1 (en) 2004-05-17 2011-11-04 Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11111954.8A HK1157637A1 (en) 2004-05-17 2011-11-04 Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections

Country Status (19)

Country Link
US (4) US7943118B2 (de)
EP (3) EP2316419B1 (de)
JP (1) JP4745340B2 (de)
AR (1) AR048793A1 (de)
AT (1) ATE493969T1 (de)
AU (2) AU2005244153B2 (de)
BR (1) BRPI0509026A (de)
CA (1) CA2564546C (de)
CY (3) CY1112004T1 (de)
DE (1) DE602005025754D1 (de)
DK (3) DK2266534T3 (de)
ES (3) ES2388420T3 (de)
HK (2) HK1151191A1 (de)
IL (2) IL179277A (de)
PL (3) PL1750667T3 (de)
PT (3) PT2316419E (de)
SI (3) SI2266534T1 (de)
TW (1) TWI409074B (de)
WO (1) WO2005110022A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1750667T3 (pl) 2004-05-17 2011-06-30 Gilead Sciences Inc Aerozolizowana kombinacja fosfomycyny/aminoglikozydu do leczenia bakteryjnych zakażeń oddechowych
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
WO2008043825A2 (en) 2006-10-11 2008-04-17 Laboratoires Smb S.A. Pharmaceutical anti-infective composition for inhalation.
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
EP2018864A1 (de) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmazeutische Zusammensetzung, Substrat mit einer pharmazeutischen Zusammensetzung und Verwendung einer pharmazeutischen Zusammensetzung
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
US20110230431A1 (en) * 2008-10-21 2011-09-22 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
EP2504013A1 (de) 2009-11-24 2012-10-03 Gilead Sciences, Inc. Inhalatives fosfomycin/tobramycin zur behandlung von chronisch obstruktiver lungenerkrankung (copd)
US8642039B2 (en) * 2009-12-22 2014-02-04 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
WO2012030513A2 (en) * 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP2014523909A (ja) * 2011-07-12 2014-09-18 カーディアス ファーマ コーポレイション 人工呼吸器関連肺炎（ｖａｐ）及び人工呼吸器関連気管（ｖａｔ）気管支炎の治療のためのアミカシンとホスホマイシンの組み合わせの製剤並びに方法及びシステム
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
PL2567691T3 (pl) * 2011-09-12 2015-05-29 Meiji Seika Pharma Co Ltd Kompozycje wodne obejmujące arbekacynę
JP2016534122A (ja) * 2013-08-26 2016-11-04 カーディアス・ファーマ・コーポレイションＣａｒｄｅａｓ Ｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ 改善された化学特性を有するアミノグリコシドおよびホスホマイシンの組合せ製剤
EP3219305A1 (de) * 2016-03-16 2017-09-20 Apostolos Georgopoulos Fosfomycin-formulierung zur parenteralen verabreichung
WO2024086892A1 (en) * 2022-10-26 2024-05-02 The George Institute for Global Health Stable api formulations comprising micronized tobramycin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750919A (en) 1980-09-16 1982-03-25 Meiji Seika Kaisha Ltd Agent for reducing side effect
JPS58134028A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) * 1991-02-15 1991-04-03 Waverley Pharma Ltd Transfer adaptor
US5488038A (en) * 1992-11-27 1996-01-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JPH09183730A (ja) 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
EP1033133A4 (de) * 1997-10-03 2004-09-01 Meiji Seika Kaisha Zusammensetzung und verfahren zur behandlung von diabetes
CN1348377A (zh) 1998-12-17 2002-05-08 希龙公司 用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002258563A1 (en) 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
ATE322249T1 (de) * 2001-05-18 2006-04-15 Chiron Corp System zur abgabe einer tobramycin-formulierung
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
AU2002350622B2 (en) * 2001-10-24 2006-09-14 Pari Pharma Gmbh Kit for the preparation of a pharmaceutical composition
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
PL1750667T3 (pl) * 2004-05-17 2011-06-30 Gilead Sciences Inc Aerozolizowana kombinacja fosfomycyny/aminoglikozydu do leczenia bakteryjnych zakażeń oddechowych
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based preparations of antinfectants for the treatment of lung infections
JP2010512350A (ja) 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
US20090054374A1 (en) 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AR074060A1 (es) 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
EP2504013A1 (de) 2009-11-24 2012-10-03 Gilead Sciences, Inc. Inhalatives fosfomycin/tobramycin zur behandlung von chronisch obstruktiver lungenerkrankung (copd)

Also Published As

Publication number Publication date
CA2564546A1 (en) 2005-11-24
DK2266534T3 (da) 2013-01-14
PT2266534E (pt) 2012-10-09
ES2392389T3 (es) 2012-12-10
AR048793A1 (es) 2006-05-24
EP1750667B1 (de) 2011-01-05
PL2316419T3 (pl) 2012-12-31
ES2388420T3 (es) 2012-10-15
TWI409074B (zh) 2013-09-21
US20110117030A1 (en) 2011-05-19
BRPI0509026A (pt) 2007-09-18
IL225529A0 (en) 2013-06-27
DK1750667T3 (da) 2011-04-26
WO2005110022A3 (en) 2006-04-06
SI1750667T1 (sl) 2011-04-29
WO2005110022A2 (en) 2005-11-24
ATE493969T1 (de) 2011-01-15
EP2316419A1 (de) 2011-05-04
US20130071442A1 (en) 2013-03-21
DE602005025754D1 (de) 2011-02-17
CY1112004T1 (el) 2015-11-04
IL179277A (en) 2013-04-30
CA2564546C (en) 2013-02-26
JP2007538075A (ja) 2007-12-27
US8361444B2 (en) 2013-01-29
US7943118B2 (en) 2011-05-17
IL179277A0 (en) 2007-05-15
EP1750667A4 (de) 2007-07-11
ES2358024T3 (es) 2011-05-04
US8409549B2 (en) 2013-04-02
CY1113283T1 (el) 2016-04-13
HK1157637A1 (en) 2012-07-06
AU2009243536B2 (en) 2012-03-22
PL1750667T3 (pl) 2011-06-30
EP2316419B1 (de) 2012-07-11
PL2266534T3 (pl) 2013-02-28
US8980226B2 (en) 2015-03-17
EP1750667A2 (de) 2007-02-14
EP2266534A1 (de) 2010-12-29
US20070218013A1 (en) 2007-09-20
AU2005244153B2 (en) 2009-10-29
AU2005244153A1 (en) 2005-11-24
PT1750667E (pt) 2011-03-11
SI2266534T1 (sl) 2012-12-31
EP2266534B1 (de) 2012-09-26
TW200608983A (en) 2006-03-16
US20110189103A1 (en) 2011-08-04
CY1113319T1 (el) 2016-04-13
DK2316419T3 (da) 2012-10-22
IL225529A (en) 2014-08-31
SI2316419T1 (sl) 2012-10-30
JP4745340B2 (ja) 2011-08-10
AU2009243536A1 (en) 2009-12-24
PT2316419E (pt) 2012-10-22

Similar Documents

Publication Publication Date Title
HK1151191A1 (en) Aerosolized fosfomycin/tobramycin combination for the treatment of cystic fibrosis
HK1143315A1 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
EG24526A (en) Atomizer for distributing liquids for medical purposes
ZA200902805B (en) Motion-sensing air freshener of the spray type
PL1931478T3 (pl) Dysza rozpylająca dla dwóch płynów
IL190920A0 (en) Compounds for the treatment of metabolic disorders
SG122049A1 (en) Plasma spray apparatus
EP1954356A4 (de) Sprühdüsen
EP1908527B8 (de) Elektrostatischer zerstäuber
SI1530466T1 (sl) Uporaba nintedaniba za zdravljenje pljučne fibroze
EP1819639A4 (de) Zerstäubendes behandlungsverfahren
EP1905516A4 (de) Elektrostatischer zerstäuber
IL189171A (en) Use of Fat-Glycosaminoglycan or Fat-Carboxymethyl Cellulose Couplings for the Treatment of Cystic Fibrosis Treatment
EP1986952A4 (de) Verfahren zur behandlung von mukoviszidose
ZA200704391B (en) Treatment and control of severe infections including cystic fibrosis
EP1964615A4 (de) Elektrostatischer zerstäuber
PL1945243T3 (pl) Zastosowanie kalcytoniny w leczeniu rzs
EP1928504A4 (de) Gegen die leber gerichtete gentherapie
ZA200704977B (en) Nebulizer formulation
EP1667518A4 (de) Behandlung von mukoviszidose mit gamma-tocopherol
AU2006274690A8 (en) Antitumoral compounds
GB0203808D0 (en) The treatment of cystic fibrosis
PL378089A1 (pl) Sposób mycia nebulizera mikrokapilarnego
AU2005900007A0 (en) Osteoporosis treatment having anti-hypocalcemia effect
AU2005904525A0 (en) Liver-directed Gene Therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200504